Sharma Nanoneuroscience and Nanoneuropharmacology

1. Auflage 2009
ISBN: 978-0-08-096224-5
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, Band Volume 180, 264 Seiten

Reihe: Progress in Brain Research

This volume presents articles from the leading experts in the field in nanobiotechnology, providing students and researchers with a comprehensive review of the newly emerging area of neuroscience. All aspects of nanomaterials induced alteration in brain function are considered. Basic chapters on methods and ways to enhance nano-drug delivery into the brain are presented as well as chapters on functional and structural changes in the CNS, including gene expression and related issues. Particular attention is given to possible therapeutic advancement regarding nano-drug formulation and their role in neuroprotection.

Autoren/Hrsg.

Sharma, Hari S.

Inhaltsverzeichnis

1;Cover;1
2;Other volumes in PROGRESS IN BRAIN RESEARCH;3
3;NANONEUROSCIENCE AND NANONEUROPHARMACOLOGY;4
4;Copyright Page;5
5;List of Contributors;6
6;Preface;8
7;Acknowledgments;12
8;Contents;14
9;Section I Nanodrug delivery and Imaging Techniques;16
9.1;Chapter 1 Drug delivery to the brain using colloidal carriers;18
9.1.1;Keywords;18
9.1.2;Introduction;18
9.1.3;The blood–brain barrier;18
9.1.4;Strategies to overcome BBB;20
9.1.5;Brain drug delivery strategies via colloid carriers;21
9.1.6;Conclusions;28
9.1.7;Acknowledgments;28
9.1.8;References;28
9.2;Chapter 2 Quantum dot nanotechnologies for neuroimaging;34
9.2.1;Keywords;34
9.2.2;Introduction;34
9.2.3;Semiconductor quantum dots and their utility for neurobiological imaging;35
9.2.4;Specific labeling and imaging of dissociated neurons and glial cells;36
9.2.5;Efficacy of different antibody conjugation methods to quantum dots;37
9.2.6;Labeling reactive gliosis in retinal tissue sections;45
9.2.7;Acknowledgments;48
9.2.8;References;48
9.3;Chapter 3 Colloidal systems for CNS drug delivery;50
9.3.1;Keywords;50
9.3.2;Introduction;50
9.3.3;Classification of colloidal carriers for CNS drug delivery;51
9.3.4;Assays for the assessment of the BBB crossing by colloidal systems;52
9.3.5;Parameters of colloidal systems involved in the interaction with biological systems;54
9.3.6;Surface modification of colloidal carriers for CNS drug delivery;63
9.3.7;Ability of the colloidal carriers to cross the BBB;70
9.3.8;Polymeric brain-targeted Np;71
9.3.9;Brain-targeted liposomes;74
9.3.10;Surface functionalization of the colloidal systems;76
9.3.11;Albumin Np;78
9.3.12;References;78
10;Section II Application of Nanotechnology in Brain Disease;86
10.1;Chapter 4 Applications of nanotechnology in molecular imaging of the brain;88
10.1.1;Keywords;88
10.1.2;Introduction;88
10.1.3;Molecular imaging modalities;89
10.1.4;MRI contrast agents;89
10.1.5;Targeting of iron oxide-based contrast agents;91
10.1.6;Molecular imaging of the brain;92
10.1.7;Conclusions and future perspectives;104
10.1.8;Acknowledgment;106
10.1.9;References;106
10.2;Chapter 5 Development of iron chelator–nanoparticle conjugates as potential therapeutic agents for Alzheimer disease;112
10.2.1;Keywords;112
10.2.2;Introduction;112
10.2.3;Excess metal toxicity and amyloid-beta aggregation;113
10.2.4;Metal chelation and nanoparticle delivery;113
10.2.5;Preparation and use of specific nanoparticle–chelator conjugates;115
10.2.6;Effects of chelator–nanoparticle conjugate on Ab aggregates and cytotoxicity;116
10.2.7;How might these nanoparticle conjugates enter the brain;118
10.2.8;Conclusion;120
10.2.9;Acknowledgments;121
10.2.10;References;121
11;Section III Nanoparticles Therapy and Neuroregeneration;124
11.1;Chapter 6 Carbon nanotubes as substrates/scaffolds for neural cell growth;126
11.1.1;Keywords;126
11.1.2;Introduction;126
11.1.3;Structure, properties, and functionalization of CNTs;127
11.1.4;CNTs as substrates/scaffolds for neuronal cell growth;129
11.1.5;CNTs as substrate for other neural cells;135
11.1.6;Concluding remarks;139
11.1.7;Acknowledgments;139
11.1.8;References;139
11.2;Chapter 7 Neuromodulation: deep brain stimulation, sensory neuroprostheses, and the neural–electrical interface;142
11.2.1;Keywords;142
11.2.2;Introduction;142
11.2.3;Deep brain stimulation - current status;142
11.2.4;DBS - emerging trends;143
11.2.5;Sensory neuroprostheses - current status;144
11.2.6;Sensory neuroprostheses - emerging trends;148
11.2.7;Nanotechniques to optimize the NEI;149
11.2.8;Sensory neuroprostheses and DBS - cross-fertilization;151
11.2.9;References;153
11.3;Chapter 8 Nanoparticles: transport across the olfactory epithelium and application to the assessment of brain function in health and disease;156
11.3.1;Keywords;156
11.3.2;Introduction;156
11.3.3;Nanoparticle transport into the CNS;157
11.3.4;Nanoparticles as sensors of brain cell function and toxicity;158
11.3.5;Some adverse effects of nanoparticles on the dysregulation of brain redox status;163
11.3.6;Summary;164
11.3.7;Acknowledgments;164
11.3.8;References;165
12;Section IV Nanoneurotoxicity and Nanoneuroprotection;168
12.1;Chapter 9 Nanoparticles influence pathophysiology of spinal cord injury and repair;170
12.1.1;Keywords;170
12.1.2;Introduction;171
12.1.3;Nanoparticles aggravate pathophysiology of spinal cord injury;174
12.1.4;Nanoparticles enhance drug delivery;183
12.1.5;Nanoparticles enhance therapeutic effects of drugs in the spinal cord;184
12.1.6;Nanoparticles enhance neuroprotection in SCI;185
12.1.7;Possible mechanisms of nanowired drugs-induced neuroprotection;188
12.1.8;General conclusion;189
12.1.9;Acknowledgments;190
12.1.10;References;190
12.2;Chapter 10 Solid lipid nanoparticles and microemulsions for drug delivery: the CNS;196
12.2.1;Keywords;196
12.2.2;Introduction;196
12.2.3;Solid lipid nanoparticles;197
12.2.4;Microemulsions;204
12.2.5;References;205
12.3;Chapter 11 Solid lipid nanoparticles for brain tumors therapy: state of the art and novel challenges;208
12.3.1;Keywords;208
12.3.2;Brain tumors;208
12.3.3;Drug delivery systems - solid lipid nanoparticles;211
12.3.4;Solid lipid nanoparticles and brain tumors;214
12.3.5;New therapeutical strategies;220
12.3.6;Future perspectives and novel challenges;226
12.3.7;Conclusions;231
12.3.8;Acknowledgments;232
12.3.9;References;232
12.4;Chapter 12 Brain as an HIV sequestered site: use of nanoparticles as a therapeutic option;240
12.4.1;Keywords;240
12.4.2;Introduction;240
12.4.3;References;246
12.5;Subject Index;250